Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Svedsater, L. Jacques, C. Goldfrad, E. R. Bleecker, P. M. O'Byrne, A. Woodcock (London, Manchester, United Kingdom; Winston-Salem, United States Of America; Hamilton, Canada). Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma. Eur Respir J 2013; 42: Suppl. 57, 701

Member's Comments

No comment yet.

Related content which might interest you: Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Innovative dry powder inhaler (DPI) shows improved cost-effectiveness compared with current DPIs for asthma therapy in UK primary care Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Prevalence of serious post-training inhaler technique errors made by device-naïve patients using three different dry powder inhalers (DPIs) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Clinical evaluation of fluticasone/formoterol twice daily delivered via a single dose dry powder inhaler in patients with persistent asthma Source: International Congress 2016 – Asthma management Year: 2016 Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Salmeterol/fluticasone 50/100 (SFC) dry powder inhaler (DPI) provides improved control and quality of life in patients symptomatic on inhaled corticosteroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002 In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Comparative effectiveness analysis: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate vs fluticasone propionate with spacer in children Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI) Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 The budesonide/formoterol inhaler as maintenance and reliever therapy in Maori asthmatics Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Late Breaking Abstract - Effectiveness of Fluticasone furoate/vilanterol (FF/VI) compared to usual care (UC) in patients with asthma: The Salford Lung Study (SLS) Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 LATE-BREAKING ABSTRACT: Effectiveness of training session on the inhalation technique of the BA-pMDI Autohaler® (containing beclometasone) in daily practice. Source: Annual Congress 2013 –Improving educational programmes for patients and multidisciplinary healthcare professionals Year: 2013 Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016